Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2017

Date: July 11, 2017
Pages: 77
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: R0F7568D245EN
Leaflet:

Download PDF Leaflet

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2017
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2017, provides an overview of the Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline landscape.

When the liquid content of the stomach refluxes into the oesophagus, that condition is called Gastroesophageal reflux disease (GERD). It is a chronic condition. The symptoms of GERD are nausea, heartburn and vomiting. The predisposing factors include eating large meals, which can cause the Lower Esophageal Sphincter (LES) to open inappropriately, as well as obesity, pregnancy, greasy food and certain drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 5, 5 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Overview
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Companies Involved in Therapeutics Development
Ahn-Gook Pharmaceutical Co Ltd
Cempra Inc
Daewoong Pharmaceutical Co Ltd
Eisai Co Ltd
Ilyang Pharmaceutical Co Ltd
Ironwood Pharmaceuticals Inc
Jeil Pharmaceutical Co Ltd
RaQualia Pharma Inc
Takeda Pharmaceutical Company Ltd
Wockhardt Ltd
Yooyoung Pharm Co Ltd
Yuyu Pharma Inc
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Drug Profiles
(lansoprazole + omeprazole) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ceclazepide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CEM-031 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexlansoprazole DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DWJ-1367 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DWP-14012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E-3710 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-17DT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ilaprazole DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IW-3718 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JP-1366 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naronapride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
netazepide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pantoprazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00000774 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Potassium Transporting ATPase Alpha Chain 1 Inhibitor for Peptic Ulcers and Reflux Esophagitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Tubulin for Barrett's Esophageal Adenocarcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tegoprazan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tenatoprazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YY-DXR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YYD-601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Product Development Milestones
Featured News & Press Releases
Mar 09, 2017: Ironwood Pharmaceuticals provides update on key pipeline program IW-3718 at R&D Day 2017
Nov 16, 2016: Renexxion Achieves Positive FDA Guidance for Phase 3-ready GI Drug Naronapride
Jul 11, 2016: Takeda Announces FDA Approval of Dexilant (dexlansoprazole) for Patients 12-17 Years of Age
Mar 23, 2016: Ironwood Pharmaceuticals Initiates Phase IIb Clinical Trial of IW-3718 in Refractory Gastroesophageal Reflux Disease
Feb 18, 2016: RaQualia Receives a Patent Allowance for Acid Pump Antagonist in Korea
Jan 27, 2016: FDA Approves Takeda’s Dexilant SoluTab (dexlansoprazole)
Oct 19, 2015: Ironwood Highlights Refractory GERD Research at the American College of Gastroenterology 2015 Annual Scientific Meeting
Feb 04, 2015: Ironwood Reports Positive Top-Line Data from Exploratory Phase IIa Trial Of IW-3718 in Refractory Gastroesophageal Reflux Disease
Mar 18, 2014: Ironwood Pharmaceuticals Initiates Phase II Clinical Study of IW-3718 in Refractory Gastroesophageal Reflux Disease
Dec 19, 2013: Dexlansoprazole, a New Dual-Delayed Release Technology for the Treatment Of Reflux Disease, Accepted for National Approvals Within the European Union
Dec 19, 2013: Dexlansoprazole, a New Dual-Delayed Release Technology for the Treatment Of Reflux Disease, Accepted for National Approvals Within the European Union
Oct 15, 2013: TWi Pharmaceuticals Comments on Dexilant Ruling
Sep 04, 2012: Santarus Announces Appellate Court Reversal In Part Of Zegerid Invalidity Decision
Nov 17, 2011: Takeda Provides Update On DEXILANT Product Labeling
Jul 27, 2011: Ilyang Pharmaceuticals Obtains Patent For Ilaprazole
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ahn-Gook Pharmaceutical Co Ltd, H2 2017
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Cempra Inc, H2 2017
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Eisai Co Ltd, H2 2017
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ilyang Pharmaceutical Co Ltd, H2 2017
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ironwood Pharmaceuticals Inc, H2 2017
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by RaQualia Pharma Inc, H2 2017
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Wockhardt Ltd, H2 2017
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Yooyoung Pharm Co Ltd, H2 2017
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Yuyu Pharma Inc, H2 2017
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, H2 2017
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, H2 2017 (Contd..1), H2 2017
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, H2 2017 (Contd..2), H2 2017
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products, H2 2017
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products, H2 2017 (Contd..1), H2 2017

LIST OF FIGURES

Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
Skip to top


Alzheimer's Disease - Pipeline Review, H2 2017 US$ 2,500.00 Aug, 2017 · 1216 pages
Huntington's Disease - Pipeline Review, H2 2015 US$ 2,000.00 Nov, 2015 · 311 pages

Ask Your Question

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: